The stock of Acorda Therapeutics Inc (NASDAQ:ACOR) is a huge mover today! About 450,151 shares traded hands. Acorda Therapeutics Inc (NASDAQ:ACOR) has declined 45.26% since March 10, 2016 and is downtrending. It has underperformed by 52.78% the S&P500.
The move comes after 6 months positive chart setup for the $898.83M company. It was reported on Oct, 13 by Barchart.com. We have $29.50 PT which if reached, will make NASDAQ:ACOR worth $422.45 million more.
Analysts await Acorda Therapeutics Inc (NASDAQ:ACOR) to report earnings on October, 27. They expect $-0.21 earnings per share, down 290.91% or $0.32 from last year’s $0.11 per share. After $-0.13 actual earnings per share reported by Acorda Therapeutics Inc for the previous quarter, Wall Street now forecasts 61.54% negative EPS growth.
Acorda Therapeutics Inc (NASDAQ:ACOR) Ratings Coverage
Out of 2 analysts covering Acorda Therapeutics (NASDAQ:ACOR), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Acorda Therapeutics has been the topic of 8 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Tuesday, August 25 by Stifel Nicolaus. The firm has “Outperform” rating by Cowen & Co given on Tuesday, August 25. Aegis Capital maintained Acorda Therapeutics Inc (NASDAQ:ACOR) on Wednesday, January 6 with “Buy” rating. The rating was initiated by Raymond James on Tuesday, September 1 with “Market Perform”. The rating was initiated by Goldman Sachs with “Neutral” on Wednesday, March 30. The stock has “Buy” rating given by TheStreet on Tuesday, August 25. JP Morgan maintained Acorda Therapeutics Inc (NASDAQ:ACOR) on Tuesday, August 25 with “Neutral” rating. The stock has “Buy” rating given by Aegis Capital on Tuesday, September 1.
According to Zacks Investment Research, “Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company’s lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.”
Insitutional Activity: The institutional sentiment decreased to 1.13 in Q2 2016. Its down 0.28, from 1.41 in 2016Q1. The ratio turned negative, as 32 funds sold all Acorda Therapeutics Inc shares owned while 45 reduced positions. 14 funds bought stakes while 73 increased positions. They now own 43.11 million shares or 7.66% less from 46.68 million shares in 2016Q1.
Teachers holds 0.01% or 223,606 shares in its portfolio. Blackrock Limited accumulated 0% or 87,438 shares. Clinton Grp Inc has invested 0.04% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR). Brown Brothers Harriman, a New York-based fund reported 211 shares. Teachers Retirement Sys Of The State Of Kentucky has 23,970 shares for 0.01% of their US portfolio. State Bank Of New York Mellon holds 0% or 525,692 shares in its portfolio. Strs Ohio has 0.02% invested in the company for 156,100 shares. Aqr Cap Limited Liability Corp accumulated 73,151 shares or 0% of the stock. State Bank Of Montreal Can accumulated 72,382 shares or 0% of the stock. First Trust Advsrs L P has 0% invested in the company for 12,579 shares. Citigroup Inc has invested 0% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR). Goldman Sachs Grp Incorporated Inc holds 0% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR) for 292,626 shares. The Massachusetts-based Loomis Sayles And Limited Partnership has invested 0% in Acorda Therapeutics Inc (NASDAQ:ACOR). Moreover, Armistice Ltd Llc has 2.25% invested in Acorda Therapeutics Inc (NASDAQ:ACOR) for 232,000 shares. Parametric Associate Limited Liability Com reported 49,936 shares or 0% of all its holdings.
Insider Transactions: Since April 19, 2016, the stock had 0 insider purchases, and 6 sales for $296,577 net activity. Wasman Jane also sold $13,660 worth of Acorda Therapeutics Inc (NASDAQ:ACOR) on Friday, September 23. Shares for $5,205 were sold by LAWRENCE DAVID. 4,860 shares with value of $126,885 were sold by Hindman Andrew A. on Friday, May 13. Randall Lorin sold 1,488 shares worth $42,676. 1,086 Acorda Therapeutics Inc (NASDAQ:ACOR) shares with value of $30,224 were sold by RAUSCHER STEVEN M.
Another recent and important Acorda Therapeutics Inc (NASDAQ:ACOR) news was published by Streetinsider.com which published an article titled: “Acorda Therapeutics (ACOR) Announces Publication of CVT-301 Data in PD OFF Periods” on October 13, 2016.
ACOR Company Profile
Acorda Therapeutics, Inc., incorporated on March 17, 1995, is a biopharmaceutical company. The Firm is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. The Company’s commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. The Company’s research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. The Company’s Ampyra (dalfampridine) Extended Release Tablets, 10 milligrams, is used as a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets, which are short-acting drugs for the management of spasticity, and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company’s pipeline of neurological therapies addresses a range of disorders, including MS, Parkinson’s disease, chronic post-stroke walking deficits (PSWD), epilepsy and migraine.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.